Stifel Financial Corp Gemini Therapeutics, Inc. Transaction History

Stifel Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.01 $57,116 - $87,635	43,600 Added 46.57%	137,221 $225,000
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $12,444 - $17,646	-10,200 Reduced 9.82%	93,621 $158,000
Q1 2022 May 13, 2022	BUY	$1.29 - $3.08 $48,918 - $116,796	37,921 Added 57.54%	103,821 $144,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $70,983 - $118,800	29,700 Added 82.04%	65,900 $192,000
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $119,460 - $228,784	36,200 New	36,200 $146,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.